Arcturus Therapeutics Holdings, Inc. operates as a late-stage clinical mRNA medicines and vaccine company, which engages in the development of infectious disease vaccines and significant ...

Neda Safarzadeh, Sr. Director, Head of IR, PR & Marketing, Arcturus Therapeutics Holdings Inc., San Diego, CA, USA, Tel: +1-858-900-2682 Arcturus Therapeutics, based ...

Explore Arcturus Therapeutics stock price, quotes, charts and forecasts with Benzinga. Stay updated on market trends for ARCT. Arcturus Therapeutics/CSL Partnered COVID-19 Vaccine Surpasses Pfizer ...

Analysts' ratings for Arcturus Therapeutics (NASDAQ:ARCT) over the last quarter vary from bullish to bearish, as provided by 8 analysts. The table below offers a condensed view of their recent ...

Canaccord analyst Whitney Ijem lowered the firm’s price target on Arcturus Therapeutics (ARCT) to $68 from $74 and keeps a Buy rating on the shares. The firm said its 4Q24 earnings report had ...

Joseph Payne; President, Chief Executive Officer, Director; Arcturus Therapeutics Holdings Inc Andrew Sassine; Chief Financial Officer, Director; Arcturus Therapeutics Holdings Inc Padmanabh ...

H.C. Wainwright analyst Ed Arce lowered the firm’s price target on Arcturus Therapeutics (ARCT) to $60 from $63 and keeps a Buy rating on the shares. Arcturus on Thursday announced that interim ...

HC Wainwright reiterated a “buy” rating and set a $63.00 target price on shares of Arcturus Therapeutics in a research note on Friday, February 14th. BTIG Research initiated coverage on shares ...

Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and ...

Arcturus Therapeutics Holdings Inc. (ARCT) reported a wider-than-expected loss for the fourth quarter of 2024, with earnings per share (EPS) of -$1.11, missing the forecast of -$0.19. The company ...